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Activation of Human Herpesvirus Replication by Apoptosis
Alka Prasad,a Jill Remick,b Steven L. Zeichnera,c
Center for Cancer and Immunology Research, Children’s Research Institute, Children’s National Medical Center, Washington, DC, USAa; George Washington University
Medical School, Washington, DC, USAb; Departments of Pediatrics and Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington,
DC, USAc
A central feature of herpesvirus biology is the ability of herpesviruses to remain latent within host cells. Classically, exposure to
inducing agents, like activating cytokines or phorbol esters that stimulate host cell signal transduction events, and epigenetic
agents (e.g., butyrate) was thought to end latency. We recently showed that Kaposi’s sarcoma-associated herpesvirus (KSHV, or
human herpesvirus-8 [HHV-8]) has another, alternative emergency escape replication pathway that is triggered when KSHV’s
host cell undergoes apoptosis, characterized by the lack of a requirement for the replication and transcription activator (RTA)
protein, accelerated late gene kinetics, and production of virus with decreased infectivity. Caspase-3 is necessary and sufficient to
initiate the alternative replication program. HSV-1 was also recently shown to initiate replication in response to host cell apop-
tosis. These observations suggested that an alternative apoptosis-triggered replication program might be a general feature of
herpesvirus biology and that apoptosis-initiated herpesvirus replication may have clinical implications, particularly for herpes-
viruses that almost universally infect humans. To explore whether an alternative apoptosis-initiated replication program is a
common feature of herpesvirus biology, we studied cell lines latently infected with Epstein-Barr virus/HHV-4, HHV-6A, HHV-
6B, HHV-7, and KSHV. We found that apoptosis triggers replication for each HHV studied, with caspase-3 being necessary and
sufficient for HHV replication. An alternative apoptosis-initiated replication program appears to be a common feature of HHV
biology. We also found that commonly used cytotoxic chemotherapeutic agents activate HHV replication, which suggests that
treatments that promote apoptosis may lead to activation of latent herpesviruses, with potential clinical significance.
Herpesviruses can productively infect cells or remain latentwithin the host cell for long periods of time, enabling herpes-
viruses to cause lifelong infections (reviewed in reference 1). For
some herpesviruses, notably gammaherpesviruses, latency is typ-
ically the default replication program. Latent virus can reactivate,
even aftermany years, and replicate lytically. Classically, the end of
latency and the initiation of lytic replication can be triggered by
activation signals, such as proinflammatory cytokines (2, 3), and
more potent activators of signal transduction cascades, such as the
diacyl glycerol homolog tetradecanoyl phorbol acetate (TPA) (4),
and by agents that alter chromatin structure, like histone deacety-
lase inhibitors such as butyrate (5).
Host cell apoptosis is clearly a threat to a latent herpesvirus: if
the host cell completes the apoptotic process before virus progeny
is produced, the virus has no chance of infecting a new cell. Pre-
sumably because host cell apoptosis poses an extreme threat, her-
pesviruses have evolved many mechanisms that aim to prevent
host cell apoptosis. For example, the Kaposi’s sarcoma-associated
herpesvirus (KSHV, or human herpesvirus-8 [HHV-8]) genome
encodes viral homologs of Flice-inhibitory protein (vFLIP) (open
reading frame [ORF] K13/vFLIP) (6), antiapoptotic homologs of
Bcl-2 (7), and a glycoprotein homologous to survivin (8), among
others. The genomes of other herpesviruses encode proteins with
analogous antiapoptotic functions (6, 9, 10).
While herpesviruses devote considerable genomic resources to
preventing their host cells from undergoing apoptosis, these ef-
forts may sometimes fail. If apoptosis proceeds, the latent virus
will not be able to successfully reproduce, but recent data suggest
that herpesviruses have another way to cope with the challenges
posed by host cell apoptosis. At least two herpesviruses apparently
can replicate via an alternative, accelerated replication pathway
that offers the virus some chance of reproducing before the com-
pletion of host cell apoptosismakes viral reproduction impossible.
We recently found, for KSHV, that when the virus detects that the
host cell is undergoing apoptosis, it adopts an emergency escape
alternative replication program (ARP) (11). The KSHV ARP is
characterized by an absence of a requirement for the replication
and transcription activator (RTA) protein, the product of open
reading frame (ORF) 50, a protein that was previously believed to
be essential for KSHV replication, an accelerated pattern of late
gene expression, and the production of large amounts of virus
with decreased infectivity. Herpes simplex virus 1 (HSV-1) has
also recently been found to have an alternative replication pro-
gram triggered by host cell apoptosis in a caspase-3-dependent
manner, in the case of HSV-1, in latently infected ganglion cells
when nerve growth factor (NGF) activity was withdrawn by expo-
sure to anti-NGF monoclonal antibody (12, 13). The alternative
apoptosis-associated replication programofHSV-1 also has a dys-
regulated pattern of gene expression.
Given that HSV-1, an alphaherpesvirus, apparently has an
apoptosis-initiated ARP (12, 13) and our recent findings that the
gammaherpesvirus KSHV had an ARP (11), we hypothesized that
an ARP may be a universal feature of herpesvirus biology and
decided to explore that hypothesis by determining if human beta-
herpesviruses, represented by HHV-6A, -6B, and -7, and another
human gammaherpesvirus, Epstein-Barr virus (EBV, or HHV-4),
had apoptosis-initiated replication programs. In addition to the
fact that these viruses represent a cross-section of human herpes-
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virus families, we also chose these herpesviruses because good
latently infected cell linemodel systems exist for them and because
they cause close to universal infections in humans by an early age
(14–17), making the clinical and translational implications of the
studies more compelling. These viruses have been associated with
significant adverse clinical outcomes in clinical situations inwhich
substantial numbers of cellsmay be undergoing apoptosis, such as
treatment with cytotoxic cancer chemotherapeutic agents, solid
organ and bone marrow transplantation (18, 19), and severe hy-
persensitivity and autoimmune disorders (20–24), and in patients
critically ill from a variety of causes (25). Human herpesviruses
have been implicated in a variety of incompletely understood clin-
ical disorders (26), some of which may be associated with apop-
tosis. EBV is also known to cause lymphomas and nasopharyngeal
carcinoma (reviewed in references 27 and 28).
We found that apoptosis, or more specifically, caspase-3 activ-
ity, triggers the replication of EBV and of HHV-6A, -6B, and -7,
which along with the previously published studies (11, 13) show-
ing that caspase-3 activity triggers the replication of KSHV and
HSV-1, suggests that apoptosis initiation of viral replication via a
caspase-3-dependent mechanism is a widespread feature of her-
pesvirus biology. We also found that apoptosis triggered herpes-
virus replication when the cells latently infected with the viruses
were treated with commonly employed cytotoxic cancer chemo-
therapeutic agents. Since several herpesviruses, including EBV,
and HHV-6A, -6B, and -7, cause close to universal infections in
humans, the findings imply that exposure to conditions that pro-
mote apoptosis may broadly activate latent herpesviruses within
most or all humans, with potentially significant negative clinical
consequences.
MATERIALS AND METHODS
Cell culture.BCBL-1 cells (29) latently infectedwithKSHVwere obtained
from the NIH AIDS Reference Reagent Program. LCLa cells (30) latently
infected with EBV were the kind gift of Jeff Cohen, NIAID, NIH. HSB2
cells (31) latently infected with HHV-6A, Sup-T1/Z29 cells (32) latently
infected with HHV-6B, and Sup-T1/JI cells (33) latently infected with
HHV-7 were obtained from the NIH AIDS Reference Reagent Program,
with the kind help of Dharam Ablashi, HHV-6 Foundation. Cells were
grown and maintained in RPMI 1640 medium enriched with 10% fetal
bovine serum (FBS), glutamine, penicillin-streptomycin, and -mercap-
toethanol (standard growth medium) in 5% CO2 at 37°C. The cell densi-
ties were maintained at between 0.25  106 and 0.5  106 cell/ml. Cell
viability and density were monitored using a hemocytometer and trypan
blue staining, and viability was maintained at90%.
Lytic replication was induced by adding tetradecanoyl phorbol-13-
acetate (TPA) (Sigma-Aldrich) at a final concentration of 20 ng/ml to the
medium. BCBL-1 cells were incubated with TPA for 1 h, LCLa cells were
incubated for 3 h, and HSB2 cells, Z29/SupT-1, and SupT-1/JI cells
were incubated for 6 h at 37°C. Following incubation with TPA, cells
were washed in medium and returned to the incubator.
Protected viral DNA isolation. Protected viral DNA was quantitated
using reverse transcription-PCR (RT-PCR) assays, using a modification
of a previously described procedure (11). In brief, supernatants from each
treatment condition were centrifuged at 5,000  g for 5 min, and the
clarified supernatant was incubatedwith RQDNase 1 (Promega) at a final
concentration of 100 U/ml and incubated at 37°C for 1 h to digest free
DNA unprotected in virions. The samples were then treated with 0.5 M
EDTA to a final concentration of 10mMand incubated at 65°C for 30min
to inactivate DNase. The samples were treated with 10% SDS to a final
concentration of 0.5% and with proteinase K to a final concentration of
200g/ml and incubated at 65°C for 2 h to disrupt the envelope and digest
capsid protein. These samples were extracted with phenol-chloroform-
isoamyl alcohol (25:24:1) (Invitrogen), followed by precipitation with
ethanol, dried, and dissolved in Tris-EDTA (TE) buffer.
Quantitation of protected viral DNA.Protected viralDNAwas quan-
tified using a TaqMan real-time PCR assay for conserved viral sequences.
For KSHV we used primers and probes specific for ORF57: ORF57 Taq-
Man probe 57TM (5=-FAM-AGAAACCGCAGCCGCCGGAG-TAMRA-
3=, where FAM is 6-carboxyfluorescein and TAMRA is 6-carboxytetra-
methylrhodamine), the forwardprimer5=-TTTGTGACCAGTTTGTTCCT
CCACGAAAGCCCC-3=, and the reverse primer 5=-TCATTTGTTCCTC
CACGAAAGCCCC-3= (Applied Biosystems). For EBVweused sequences
in BALF5: TaqMan probe BALF5TM (5=-FAM-TGTACACGCACGAGA
AATGCGCC-TAMRA-3=), the forward primer 5=-CGGAAGCCCTCTG
GACTTC-3=, and the reverse primer 5=-CCCTGTTTATCCGATGGAAT
G-3= (IntegratedDNATechnologies, IDT). ForHHV-6A and -6Bwe used
sequences in U38. For HHV-6A we used TaqMan Probe U38TM (5=-FA
M-TGCAGCCATTTCTTTGGAAAGC-TAMRA-3=), and for HHV-6B
we used TaqMan probe U38TM (5=-FAM-TGCAGCCACCTCCTTGGA
AAG-TAMRA-3=). For HHV-6A and HHV-6B we used the forward
primer 5=-GGAGTGCCTGTGGGTATTC-3= and the reverse primer 5=-C
TAAGGTGACCAGATTCG-3= (IDT). For HHV-7 we used sequences in
U100: TaqMan probe for HHV-7U100TM (5=-FAM-ATGAAAACATGC
ACAACGCAAGCTCT-TAMRA-3=), the forward primer5=-AGCTTTGT
CTTTCCTCGGAAC-3=, and the reverse primer 5=-ACGCACGGCAATA
ACTCTAG-3= (IDT). Real-time PCR assays were performed using an
Applied Biosystems 7900 HT Fast Real-Time PCR System. All assays were
performed in triplicate.
Assays for second-round production of infectious virions. We col-
lected supernatants from the cell lines latently infected with HHV-6A,
HHV-6B, or HHV-7 after inducing viral replication with either TPA or
the apoptosis inducer DCPE [2-(3-(2,3-dichlorophenoxy)propylamino)
ethanol] and added 200 l of supernatant from each condition to Jurkat
cells, which can support productive infection of HHV-6 (34). After 24 h,
supernatants from the Jurkat cells were subsequently assayed for pro-
tected viral DNA, as described above.
Induction and determination of apoptosis. BCBL-1, LCLa, HSB2,
Z29/SupT-1, and SupT-1/JI cells were seeded overnight at a concentration
of 0.25  106 cells/ml. Apoptosis was induced by adding DCPE (2,3-
DCPEHCl; Enzo Life Sciences) at a final concentration of 50 nM, and cells
were incubated at 37°C for 24 h. The cells were harvested by centrifugation
at 150  g after assessment of cell number and viability. Supernatants
were used for protected viral DNA isolation and quantitation as described
above. Cell pellets were washed with phosphate-buffered saline (PBS)
(without calcium andmagnesium) at pH 7.4 and analyzed by flow cytom-
etry or stained for immunofluorescence assays.
Apoptosis was assessed using a fluorescein isothiocyanate (FITC)
Annexin V Apoptosis Detection Kit I (BD Pharmingen) to determine cell
surface phosphatidylserinewith flow cytometry. In these experiments, 106
cells from each treatment condition were resuspended in 100 l of 1
binding buffer, followed by the addition of fluorescein-conjugated
annexin V and propidium iodide (annexin-PI; 50g/ml in 1 PBS). The
cells were incubated for 15 min at room temperature (RT) and analyzed
by flow cytometry (FACSCalibur; BD Biosciences). Untreated cells were
used to establish forward and side scatter gates for compensation base-
lines. Data were analyzed using FlowJo, version 8.5.2, software (FlowJo,
Ashland, OR).
Confocal microscopy for EBV p52, HHV-6A gp116, HHV-6B gp116,
HHV-7 KR4, and the KSHV late gene ORFK8.1. Detection of viral pro-
tein expression was performed by immunofluorescence using a confocal
Zeiss LSM 510 microscope. Coverslips in 24-well plates were coated with
poly-L-lysine and incubated at RTovernight. Cells (0.5 106 to 1.0 106)
from each treatment condition were pelleted and then resuspended in
RPMI 1640 medium. The cells were transferred to coated coverslips in
24-well plates and allowed to settle for 15min, washedwith PBS, and fixed
with 4%paraformaldehyde at 4°C for 30min. The cells were washed twice
with PBS and permeabilized with PBS containing 0.1% Triton X-100 at
Prasad et al.
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RT for 10 min. The cells were washed twice with PBS and incubated with
mouse monoclonal antibodies against KSHV ORFK8.1 (Advanced Bio-
technologies, Inc.), EBV p52, HHV-6A gp116, HHV-6B gp116, and
HHV-7 KR4 (NIHAIDS Research and Reference Reagent Program), each
at a 1:400 dilution in PBS, and incubated overnight at 4°C. The cells were
washed twice with PBS and incubated with goat anti-mouse secondary
antibody conjugated to peridinin chlorophyll protein (PerCP; Santa Cruz
Biotechnology) at a dilution of 1:1,000 in PBS for 2 h at room tempera-
ture. Cells from each treatment condition were resuspended in 100 l of
1 binding buffer, followed by incubation with allophycocyanin-conju-
gated annexinV (APCAnnexinV; Life Technologies) in the dark at RT for
15 min to stain for apoptotic cells. The coverslips were mounted on slides
with ProlongGold antifade reagent with 4=,6=-diamidino-2-phenylindole
(DAPI) (Invitrogen) as a nuclear stain. A magnification of40 (oil) was
used to acquire all images.
Transfection of cells with a plasmid expressing a caspase-3–GFP fu-
sion protein. Cell lines latently infected with herpesviruses were trans-
fected with a plasmid, pcasp3-WT-GFP, that expresses functional wild-
type (WT) caspase-3 fused to green fluorescent protein (GFP), a kind gift
from Shinji Kamada, Biosignal Research Center, Kobe University (35).
pUC19 was used as a negative control. APC-annexin V (BD Pharmingen)
was used to detect apoptosis. Monoclonal antibodies against EBV p52,
HHV-6A gp116, HHV-6B gp116, and HHV-7 KR4 (NIH AIDS Research
and Reference Reagent Program) and KSHV ORFK8.1 (Advanced Bio-
technologies, Inc.), each at 1:400 dilution, and goat anti-mouse secondary
antibody labeled with PerCP (Advanced Biotechnologies) were used to
detect viral protein expression. Cells were seeded in 24-well plates, and 2 h
prior to transfection, the medium was replaced by RPMI 1640 medium
with no FBS and antibiotics. Lipofectamine 2000 (Invitrogen) was mixed
with Opti-MEM Imedium (Invitrogen) at a 1:25 dilution and kept for 10
min at RT. This mixture was then complexed with 500 ng of pcasp3-WT-
GFP at a ratio of 1:1 and kept at RT for 30 min. Two hundred microliters
of this complex was added for transfection in each well. The plates were
gently rocked at 37°C for 5 h. TPA (20 ng/ml) was added to selected wells
and incubated for 1 h. DCPE (final concentration, 50 nM) was added to
selected samples.
Inhibition of apoptosis and viral DNA replication by a caspase-3
inhibitor. To study the effects of a caspase-3 inhibitor on cell apoptosis
and viral replication, cell lines latently infected with herpesviruses were
treated with the caspase-3 inhibitor acetyl (Ac)-AAVALLPAVLLAPDGV
D-CHO (Enzo Life Sciences). The caspase-3 inhibitor was reconstituted
in dimethyl sulfoxide (DMSO) (Fisher Scientific) to a stock concentration
of 10 mM. Cells were seeded in six-well plates at a density of 0.25  106
cells/ml and treated with the caspase-3 inhibitor at final concentrations of
50 to 250 M in the presence of DCPE (50 nM). Some cells were treated
with TPA (20 ng/ml) as a positive control to induce viral replication.
The cells were harvested after 24 h. Supernatants were used to assay for
herpesvirus replication as described above. Approximately 106 cells
from each treatment condition were resuspended in 100 l of 1
binding buffer, followed by staining with fluorescein-conjugated
annexin V and propidium iodide (FITC Annexin V Apoptosis Detec-
tion Kit I) (BD Pharmingen). The cells were incubated in the dark for
15 min at room temperature (RT) and analyzed by flow cytometry
(FACSCalibur; BD Biosciences). Data were analyzed using FlowJo,
version 8.5.2, software.
Induction of apoptosis and viral replication by cytotoxic chemo-
therapy agents.Cell lines latently infectedwith herpesviruseswere treated
with the cytotoxic chemotherapeutic agents doxorubicin, prednisone,
and vincristine (Sigma-Aldrich). Doxorubicin was reconstituted in mo-
lecular-grade water at a stock concentration of 100 M, prednisone was
reconstituted at a stock concentration of 100 M in absolute ethanol
(Sigma-Aldrich), and vincristine was reconstituted in molecular biology-
grade water at a stock concentration of 100 M. Cells were seeded in
24-well plates at a density of 0.25 106 cells/ml 12 h prior to treatment.
The cells were treatedwith chemotherapy agents at final concentrations of
0.1M, 0.5M, 1.0M, 5.0M, and 10.0M.Cells were harvested after
24 h by centrifugation at 5,000 g for 5 min. The amounts of protected
viral DNA in the supernatants were assayed by TaqMan quantitative PCR
(qPCR) as described above. Cell pellets were washed in PBS and stained
for apoptosis assay as described above using an FITC Annexin V Apopto-
sis Detection Kit I (BD Pharmingen).
RESULTS
Apoptosis-associated induction of viral replication in cells la-
tently infected with EBV, HHV-6A, HHV-6B, HHV-7, and
KSHV. To test the hypothesis that apoptosis broadly activates
replication among clinically significant Herpesviridae, we studied
LCLa cells (30) latently infectedwith EBV,HSB2 cells (31) latently
infected with HHV-6A, Sup-T1/Z29 cells (32) latently infected
with HHV-6B, and Sup-T1/JI cells (33) latently infected with
HHV-7. As a positive control, we also studied BCBL-1 cells la-
tently infected with KSHV (29). We treated aliquots of the cells
with DCPE to induce apoptosis and treated additional aliquots of
the cells with TPA as a positive control for induction of viral rep-
lication through a non-apoptosis-mediated pathway.
After the treatments, we examined the cells with confocal mi-
croscopy by staining nuclei with DAPI, assessing apoptosis using
an annexin stain, and evaluating induction of viral protein expres-
sion by staining for a viral protein for each virus (KSHVORFK8.1,
EBV p52, HHV-6A gp116, HHV-6B gp116, and HHV-7 KR4)
using a primary mouse antiviral monoclonal antibody and a
PerCP-conjugated goat anti-mouse secondary antibody. Figure 1
shows that TPA did not induce apoptosis but did induce viral
protein expression in all of the latently infected cells, so the cell
lines were fully capable of being induced and expressing viral pro-
teins.Whenwe treated the cells with the apoptosis inducer DCPE,
we found (Fig. 2) that DCPE induced both apoptosis and viral
protein expression for all the cell lines latently infected with her-
pesviruses that we studied.
Caspase-3-associated induction of viral replication in cells
latently infected with EBV, HHV-6A, HHV-6B, HHV-7, and
KSHV. Since the apoptosis inducer DCPE might have induced
viral protein expression through some other mechanism than one
linked to apoptosis and since we previously showed that apoptosis
triggered KSHV replication in a caspase-3-dependent manner
(11), we conducted experiments in which we transfected the cells
latently infected with the different herpesviruses with a plasmid,
pcasp3-WT-GFP (35), that expresses a functional caspase-3–GFP
fusion protein. The results of these experiments are shown in Fig.
3.We observed expression of the caspase-3–GFP fusion protein in
all of the herpesvirus latently infected cell lines studied, and ex-
pression was associated with induction of apoptosis, as judged by
annexin V binding; the expression of the caspase-3–GFP fusion
protein and apoptosis were associated with induction of viral pro-
tein expression, suggesting that apoptosis induced the replication
of the different herpesviruses through a caspase-3-dependent
pathway.
Apoptosis-associated, caspase-3-dependent virion produc-
tion from cells latently infected with EBV, HHV-6A, HHV-6B,
HHV-7, and KSHV. To show that apoptosis induced not only the
expression of viral protein but also the formation of virion parti-
cles, we used a TaqMan qPCR assay for protected viral DNA (11,
36, 37), as we previously described for KSHV, modified using the
appropriate primers and probes for the other herpesviruses (Fig.
4). We found that the apoptosis inducer DCPE induced the pro-
Apoptosis Activation of Herpesvirus Replication
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duction of herpesvirus virions in all of the herpesvirus latently
infected cell lines studied, suggesting that host cell apoptosis trig-
gers not only the expression of herpesvirus proteins but also the
production of herpesvirus virions across a broad selection of hu-
man herpesviruses. We treated the cells with the caspase-3 inhib-
itor (Ac)-AAVALLPAVLLAPDGVD-CHO and found that the
caspase-3 inhibitor blocked both host cell apoptosis and produc-
tion of virions in a parallel fashion for all of the herpesviruses
studied (EBV, HHV-6A, HHV-6B, HHV-7, and KSHV), provid-
ing another line of evidence that activation of the viruses in asso-
ciation with apoptosis depends on the activity of caspase-3.
To show that the virions produced in association with apopto-
sis were, in fact, functional infectious virions, we assayed superna-
FIG 1 Induction of viral protein expression in herpesvirus latently infected
cells treatedwithTPA. BCBL-1 cells latently infectedKSHV, LCLa cells latently
infected with EBV, HSB2 cells latently infected with HHV-6A, Z29/SupT-1
cells latently infected with HHV-6B, and SupT-1/JI cells latently infected with
HHV-7 were treated with TPA and examined at 24 h. Cells were stained with
the nuclear stain DAPI (blue), stained with annexin V-APC (red) to assay for
apoptosis, and incubatedwithmousemonoclonal antibodies against viral pro-
teins (EBV p52, HHV-6A gp116, HHV-6B gp116, HHV-7 KR4, and the KSHV
late gene ORFK8.1) followed by incubation with secondary antibodies conju-
gated to PerCP (yellow). Cells were examined using confocal microscopy.
Upon TPA treatment, all the cell lines showed minimal evidence of apoptosis
(red) and high viral protein expression (yellow).
FIG 2 Apoptosis induces viral protein expression in herpesvirus latently in-
fected cells. BCBL-1 cells latently infected with KSHV, LCLa cells latently in-
fected with EBV, HSB2 cells latently infected with HHV-6A, Z29/SupT-1 cells
latently infected with HHV-6B, and SupT-1/JI cells latently infected with
HHV-7 were treated with the proapoptotic agent DCPE and examined at 24 h.
Cell nuclei were stained with DAPI (blue), and cells were stained with annexin
V-APC (red) to detect cells undergoing apoptosis. Cells were incubated with
mousemonoclonal antibodies against specific viral proteins (KSHVORFK8.1,
EBV p52, HHV-6A gp116, HHV-6B gp116, and HHV-7 KR4), followed by
incubation with goat anti-mouse secondary antibody conjugated to PerCP
(yellow), and examined with confocal microscopy. Almost all the cells ap-
peared to be undergoing apoptosis, which was associated with viral protein
expression (yellow).
Prasad et al.
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tants from cells latently infected with viruses for which there are
efficient acute viral replication systems.We collected supernatants
from cells latently infected with HHV-6A, HHV-6B, and HHV-7
and exposed Jurkat cells to these supernatants. Following expo-
sure to the cell supernatants, we assayed for the production of a
second round of virions, using the assay for protected viral DNA
(Fig. 5). We found that for each of the viruses studied, HHV-6A,
HHV-6B, and HHV-7, the supernatants following induction of
viral replication either by the control inducer TPA or the inducer
of apoptosis DCPE contained infectious virus, so apoptosis can
induce not only the production of viral DNA but also the produc-
tion of infectious virions.
Apoptosis and caspase-3-associated induction of viral repli-
cation in cells latently infected with EBV, HHV-6A, HHV-6B,
HHV-7, and KSHV after treatment with cytotoxic chemother-
apy agents. Since the herpesviruses we studied in these experi-
ments, particularly HHV-6A, -6B, and -7, infect humans almost
universally in the first years of life, it may be important to consider
whether proapoptotic agents and disorders that humans may be
exposed to later in life are also capable of inducing the replication
of these herpesviruses. Some of the kinds of proapoptotic agents
that patients may be exposed to are cancer chemotherapeutic
agents. We therefore tested three different agents commonly used
in cancer chemotherapy that act by different mechanisms, the
anthracycline DNA intercalator doxorubicin, the vinca alkaloid
microtubule inhibitor vincristine, and the glucocorticoid predni-
sone. In these experiments (Fig. 6), we assessed apoptosis flow
cytometrically and in parallel evaluated herpesvirus replication by
assaying for protected herpesvirus DNA in the cell supernatants.
We found that doxorubicin, vincristine, and prednisone induced
apoptosis in all of the herpesvirus latently infected cell lines and
induced herpesvirus replication in those cell lines in a caspase-3-
dependent fashion. These studies also confirmed, using a different
flow-cytometric approach than the approach used in the experi-
ments shown in Fig. 1 to 4, that TPA induced viral replication
without inducing apoptosis, that DCPE induced both apoptosis
and viral replication, and that the induction of viral replication by
apoptosis required caspase-3 activity.
FIG 3 Caspase-3 induces apoptosis in cell lines latently infected with herpesviruses and is associated with herpesvirus protein expression. BCBL-1 cells
latently infected with KSHV, LCLa cells latently infected with EBV, HSB2 cells latently infected with HHV-6A, Z29/SupT-1 cells latently infected with
HHV-6B, and SupT-1 cells latently infected with HHV-7 were transfected with pcas3-WT-GFP, which expresses caspase-3 as a GFP fusion protein, or
pUC19 as a negative control. Cells were stained with annexin V-APC (red) to assay apoptosis. Cell nuclei were stained with DAPI (blue). Cells were
incubated with mouse monoclonal antibodies against specific viral proteins (KSHV ORFK8.1, EBV p52, HHV-6A gp116, HHV-6B gp116, and HHV-7
KR4), followed by incubation with goat anti-mouse secondary antibody conjugated to PerCP (yellow), and examined with confocal microscopy.
Caspase-3 expression, shown as GFP expression (green), was associated with high levels of apoptosis (red) and also with viral protein expression (yellow)
in all of the herpesvirus latently infected cell lines.
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FIG 4 The proapoptotic agent DCPE induces cell death and viral replication in cell lines latently infected with herpesviruses in a caspase-3-dependent process.
Cell lines latently infected with herpesviruses, BCBL-1 cells latently infected KSHV, LCLa cells latently infected with EBV, HSB2 cells latently infected with
HHV-6A, Z29/SupT-1 cells latently infected with HHV-6B, and SupT-1/JI cells latently infected with HHV-7 were treated with TPA to induce viral replication
through the conventional pathway as a positive control andwith the proapoptotic agentDCPE to induce apoptosis. Aliquots of the cells treatedwith the apoptotic
inducer DCPE were also treated with various concentrations of a caspase-3 inhibitor. Cells were stained with annexin V-FITC and propidium iodide (PI) and
assayed for apoptosis using flow cytometry. Cell supernatants were assayed for viral DNA replication using a viral DNATaqMan assay. DCPE induced apoptosis,
which was blocked by the caspase-3 inhibitor in a dose-dependent manner. All of the herpesvirus latently infected cell lines induced into apoptosis by DCPE
produced large amounts of virus, which was blocked in a dose-dependent manner by the caspase-3 inhibitor.
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DISCUSSION
Overall, the results show that several different human herpesvi-
ruses have a caspase-3-dependent apoptosis-initiated viral alter-
native replication program (ARP). These findings reinforce our
prior findings (11) that KSHV has an ARP characterized by the
lack of a requirement for the KSHV RTA transactivator, an accel-
erated pattern of late gene expression, caspase-3 dependence, and
the production of virus with still present but decreased infectivity
and the findings that HSV-1 has an ARP that is caspase-3 depen-
dent and results in a dysregulated pattern of gene expression (12,
13). These previously published findings and the findings we pres-
ent here suggest that all members of the familyHerpesviridaemay
have an apoptosis-initiated ARP. It is important to note that all of
the cells latently infected with herpesviruses examined in these
studies were transformed cell lines. It is possible that latent her-
pesviruses in transformed cell linesmay be particularly sensitive to
activation by apoptosis or that the apoptotic pathways active in
cell lines may exhibit some important differences compared to
primary cells. However, experiments involving HSV-1 (12, 13)
used a primary cell model system, ganglion explants, so it is un-
likely that apoptosis activation of herpesvirus replication is an
artifactual phenomenon restricted to the special case of trans-
formed cell lines latently infected with herpesviruses.
The existence of an apoptosis-initiated ARP makes sense evo-
lutionarily since an ARP would be the only chance for a herpesvi-
rus to replicate when apoptosis threatens the host cell, but a firm
conclusion that all herpesviruses have an apoptosis-induced ARP
must await future studies on many other herpesviruses. The find-
ings likewise suggest that caspase-3 plays a key role in the induc-
tion of the ARP for all herpesviruses. The apoptosis-inducing
agents that we studied, DCPE, and the chemotherapeutic agents
doxorubicin, prednisone, and vincristine, act through several dif-
ferent initial pathways and can have pleiotropic effects on cells,
raising the possibility that at least someherpesvirus activationmay
result from effects other than those mediated through induction
of apoptosis. However, the ability of the caspase-3 inhibitor to
block replication following treatment with these agents argues
that apoptosis and caspase activation at least play important roles
for all of the cytotoxic agents studied. A complete understanding
of how caspase-3 activity mediates the induction of the ARP sim-
ilarly must await many future detailed additional mechanistic
studies, but one plausible hypothesis would be that there is some
viral or host cell protein that is sensitive to caspase-3-mediated
cleavage that leads to its activation as a potent transactivator. At
least one herpesvirus protein, the HSV-1 ICP-22 (38), has been
shown to be cleaved by caspase-3, but whether this protein or
another protein or other analogous proteins mediate herpesvirus
activation remains to be determined.
Our findings that the cytotoxic chemotherapeutic agents we
studied, doxorubicin, vincristine, and prednisone, which act
through distinct mechanisms, activate EBV, HHV-6A, -6B, -7,
and KSHV in a caspase-3-dependent manner confirm the model
that caspase-3 constitutes an essential factor in herpesvirus apop-
tosis sensing and the initiation of the apoptosis-initiatedARP. The
findings further suggest the possibility that these drugs may acti-
vate the herpesviruses in vivo and that other cytotoxic chemother-
apeutic agents may also activate herpesviruses latent within pa-
tients. While cytotoxic agents are known to activate herpesviruses
in tumors believed to be caused by herpesviruses, the possibility of
a general activation of latent herpesviruses by cytotoxic agents is
less well appreciated. If cytotoxic chemotherapeutic agents do
generally activate latent herpesviruses within patients via an apop-
tosis-associatedARP, the exposure of a patient to large amounts of
circulating herpesviruses replicating as a result of an ARP induced
by therapeutic interventions may have significant clinical conse-
quences. If cytotoxic chemotherapeutic agents do activate latent
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FIG 5 Production of infectious virions following induction of viral replication by the apoptotic inducer DCPE. Supernatants from the cell lines latently infected
with HHV-6A, HHV-6B, or HHV-7, induced into replication with either the conventional inducer, TPA, or the inducer of apoptosis, DCPE, were added to
uninfected Jurkat cells, and subsequently supernatants from the Jurkat cells were assayed for protected viral DNA. The Jurkat cells produced virus.
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FIG 6 Cytotoxic chemotherapeutic agents induce apoptosis and herpesvirus replication in a caspase-3-dependent manner. Cell lines latently infected with
herpesviruses, BCBL-1 cells latently infected KSHV, LCLa cells latently infected with EBV, HSB2 cells latently infected with HHV-6A, Z29/SupT-1 cells latently
infected with HHV-6B, and SupT-1/JI cells latently infected with HHV-7 were treated with TPA as a positive control for induction of the conventional
herpesvirus replication pathway, with DCPE as positive control for the induction of apoptosis, and with cytotoxic chemotherapeutic agents acting through
different mechanisms (doxorubicin, vincristine and prednisone). Aliquots of the cells treated with DCPE or the cytotoxic chemotherapeutic agents were also
treated with a caspase-3 (Cas-3) inhibitor. Cells were harvested after 24 h and stained with annexin V-FITC and propidium iodide to assay for apoptosis by flow
cytometry. Supernatants from the aliquots were assayed for protected viral DNAusing a TaqMan qPCR assay. DCPE induced apoptosis in all herpesvirus latently
infected cell lines and induced herpesvirus replication, which was blocked by the caspase-3 inhibitor. The cytotoxic chemotherapeutic drugs also induced
apoptosis in the herpesvirus latently infected cell lines, which was associated with the induction of viral replication. Both induction of apoptosis and viral
replication by the cytotoxic chemotherapeutic agents occurred in a caspase-3-dependent manner. DOXO, doxorubicin.
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herpesviruses in potentially deleterious ways, for example, by
causing culture-negative sepsis-like syndromes or by infecting he-
matopoietic cells, then it would conceivably be helpful to treat
patients at a high risk of experiencing substantial herpesvirus ac-
tivation in associationwith apoptosis induced by chemotherapeu-
tic agents with antiviral agents in addition to their antineoplastic
cytotoxic chemotherapy. Similarly, since prednisone induced the
replication of the herpesviruses via the ARP, it may be important
to consider whether treatments with high doses of glucocorticoids
generally induce herpesvirus replication in patients treated for a
variety of inflammatory and autoimmune disorders and whether
the activation of latent herpesviruses in these disordersmight have
negative clinical consequences. Indeed, it has been a long-stand-
ing clinical observation that treatment with glucocorticoids can
worsen KS (39). In most instances of herpesvirus activation by
glucocorticoids, the herpesvirus activation has been ascribed to
immunosuppression although in the instance of a prior in vitro
study in which treatment of KSHV latently infected BCBL-1 cells
with hydrocortisone was shown to activate KSHV, activation was
ascribed to immunosuppression or direct activation of the virus
through an unknown mechanism (40).
Clinically, a large number of sometimes serious states and dis-
orders that affect the host can produce apoptosis, in addition to
cytotoxic cancer chemotherapy or treatment with high doses of
glucocorticoids. Some of these have been associated with HHV
activation. These associations range from advanced age and the
activation of varicella-zoster virus (VZV) as shingles, to stress and
UV radiation and the activation of HSV-1, to cancer chemother-
apy or neoplastic diseases themselves, bone marrow transplanta-
tion, drug-induced hypersensitivity syndrome/drug reaction/rash
with eosinophilia and systemic symptoms (DIHS/DRESS) (21–
24, 41), and the activation of cytomegalovirus (CMV), EBV,
HHV-6, andHHV-7.Our findings would suggest that some, if not
many, of the HHV activation phenomena observed in association
with these disorders result from a caspase-3-dependent activation
of a herpesvirus ARP.
In some instances, herpesvirus activation has been associated
with adverse outcomes, for example, activation of CMV and EBV,
and poor outcomes following bone marrow transplantation (42)
and activation ofHHV-6 andDIHS/DRESS. Activation of herpes-
viruses in these states and disorders has previously been variably
attributed to general immune suppression, suppression of specific
arms of the immune system, and increased concentrations of in-
flammatory and activating cytokines. Our results would also indi-
cate that, at least in some cases, conditions and disorders that
induce apoptosis may themselves induce herpesvirus replication
via the apoptosis-associated emergency escapeARP. The existence
of the apoptosis-associated ARP may help to explain some of the
pathogenic features that accompany disorders associated with
apoptosis in host cells. For example, in DIHS/DRESS, activation
of HHV-6 has been proposed as one of the defining features of the
syndrome.One interpretation of our findingsmight then be that if
a hypersensitivity reaction is severe enough to induce significant
apoptosis in cells latently infected with HHV-6, apoptosis will
trigger detectable HHV-6 replication.
Our findings suggest thatmany, and perhaps all, herpesviruses,
as they exist latently within their host cells, sense the health of the
host cell and evaluate whether the host cell is threatened with
apoptosis by detecting activation of the end effector caspase,
caspase-3, and either choose to replicate in a careful, orderly fash-
ion if they do not detect caspase-3 activation or select an emer-
gency escape ARP as the only option for effective replication if
they do. If confirmed, the findings would suggest that there is a
dialog between a host cell and a latent herpesvirus within that host
cell that was not previously appreciated and that could ultimately
have important clinical consequences.
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